Target intelligence / Profile preview

Poliovirus inactivated antigen (types 1, 2, and 3) (IPV antigen)

Target
IPV antigen
Molecular classification
Other (viral antigen/non-protein, non-receptor molecule), Viral protein complex (composed of poliovirus capsid proteins: VP1, VP2, VP3, VP4), Not a classical molecular target (does not fit standard drug target categories like enzyme, receptor, ion channel, etc.)
01

Overview

The inactivated poliovirus antigen (types 1, 2, and 3) is a viral protein complex derived from poliovirus strains representing the three main serotypes (PV1, PV2, PV3), purified and chemically inactivated (typically with formalin) to eliminate infectivity while preserving key antigenic epitopes, primarily the D-antigen. These antigens are the active immunogenic ingredients in inactivated polio vaccines (IPV, sIPV) and are used to elicit protective humoral immunity in humans, preventing poliomyelitis by inducing neutralizing antibodies. The poliovirus itself is a non-enveloped, positive-sense single-stranded RNA virus of the Picornaviridae family, with a capsid composed of proteins VP1–VP4. The D-antigen configuration is critical for inducing a protective immune response and is carefully monitored during vaccine production to ensure potency and safety.

Other names
Inactivated poliovirus antigen (types 1, 2, and 3)IPV antigenPoliovirus D-antigenSabin IPVFormalin-inactivated poliovirus
02

Mechanism of action

Induction of protective neutralizing antibodies against poliovirus capsid proteins (primarily D-antigen epitopes) Antigen presentation to immune system triggers B-cell and T-cell responses, leading to long-term immunity

03

Biological functions

Induces immune response (humoral immunity; triggers production of neutralizing antibodies)Mimics native viral structure to train immune system without infectivity
04

Disease associations

Infection (used exclusively in the context of protection against poliovirus infection/poliomyelitis)Other (prophylactic/immune prophylaxis)
05

Safety considerations

Minimal direct safety concerns from the antigen itself due to complete inactivation (cannot cause infection)Vaccine-associated issues may include typical mild adverse reactions (e.g., soreness, fever)Risk of insufficient inactivation leading to live virus (extremely rare with adequate manufacturing controls)
06

Interacting drugs

Inactivated poliovirus vaccine (IPV)

2 more in the full profile.

07

Biomarkers

Neutralizing antibody titers against poliovirus serotypes 1, 2, and 3 (used as correlate of protective immunity)D-antigenicity (presence and integrity of D-antigen epitopes as a functional biomarker for potency)

Beyond the preview

Go deeper on Poliovirus inactivated antigen (types 1, 2, and 3) (IPV antigen).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Poliovirus inactivated antigen (types 1, 2, and 3) (IPV antigen).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call